F

Fate Therapeutics
D

FATE

1.34500
USD
0.03
(2.28%)
Market Closed
Volume
76,506
EPS
-2
Div Yield
-
P/E
-1
Market Cap
153,187,878
Related Instruments
    B
    BLUE
    -0.31000
    (-3.79%)
    7.86000 USD
    C
    CLLS
    0.05000
    (3.36%)
    1.54000 USD
    C
    CRSP
    2.740
    (6.61%)
    44.200 USD
    E
    EDIT
    0.15000
    (12.50%)
    1.35000 USD
    N
    NTLA
    1.040
    (10.45%)
    10.990 USD
    S
    SGMO
    0.03500
    (3.13%)
    1.15500 USD
    V
    VYGR
    0.22000
    (4.21%)
    5.45000 USD
    More
News

Title: Fate Therapeutics

Sector: Healthcare
Industry: Biotechnology
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.